Sparse multifocal stimuli for the detection of multiple sclerosis
暂无分享,去创建一个
Rasa Ruseckaite | A. James | C. Lueck | T. Maddess | R. Ruseckaite | G. Danta | Teddy Maddess | Gytis Danta | Christian J. Lueck | Andrew C. James
[1] G. McDonnell,et al. Evaluation of the clinical utility of cerebrospinal fluid (CSF) indices of inflammatory markers in multiple sclerosis. , 2000, Acta neurologica Scandinavica.
[2] J L Keltner,et al. Long- and short-term variability of automated perimetry results in patients with optic neuritis and healthy subjects. , 1998, Archives of ophthalmology.
[3] M. Moscarello,et al. A rapid ELISA-based serum assay for myelin basic protein in multiple sclerosis. , 2002, Journal of immunological methods.
[4] I. Elovaara,et al. Volumetric quantitation by MRI in primary progressive multiple sclerosis: volumes of plaques and atrophy correlated with neurological disability , 2003, European journal of neurology.
[5] S. Graham,et al. Electrode position and the multi-focal visual-evoked potential: role in objective visual field assessment. , 1998, Australian and New Zealand journal of ophthalmology.
[6] A. James,et al. Testing for glaucoma with the spatial frequency doubling illusion , 1999, Vision Research.
[7] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[8] Donald C. Hood,et al. Multifocal ERG and VEP responses and visual fields: comparing disease-related changes , 2004, Documenta Ophthalmologica.
[9] D. Jeffreys,et al. Source locations of pattern-specific components of human visual evoked potentials. I. Component of striate cortical origin , 2004, Experimental Brain Research.
[10] A. James. The pattern-pulse multifocal visual evoked potential. , 2003, Investigative ophthalmology & visual science.
[11] A. James,et al. Contrast response of temporally sparse dichoptic multifocal visual evoked potentials , 2005, Visual Neuroscience.
[12] C. Manelfe,et al. Clinical–MRI correlations in the secondary progressive phase of MS: lessons from the treatment trials , 2003, Journal of the Neurological Sciences.
[13] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.
[14] A. Compston,et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis , 1999, Annals of neurology.
[15] Donald C. Hood,et al. Normative ranges and specificity of the multifocal VEP , 2004, Documenta Ophthalmologica.
[16] S. Hillyard,et al. Cortical sources of the early components of the visual evoked potential , 2002, Human brain mapping.
[17] Charles E. Heckler,et al. Applied Multivariate Statistical Analysis , 2005, Technometrics.
[18] James P. Egan,et al. Signal detection theory and ROC analysis , 1975 .
[19] L. Elfman,et al. IL-8 and the Activation of Eosinophils and Neutrophils following Nasal Allergen Challenge , 1998, International Archives of Allergy and Immunology.
[20] S. Graham,et al. Multifocal objective perimetry in the detection of glaucomatous field loss. , 2002, American journal of ophthalmology.
[21] P. M. Matthews,et al. Evidence of early cortical atrophy in MS , 2003, Neurology.
[22] N. Fujimoto,et al. Frequency doubling perimetry in resolved optic neuritis. , 2000, Investigative ophthalmology & visual science.
[23] G. Rosati,et al. The worldwide prevalence of multiple sclerosis , 2002, Clinical Neurology and Neurosurgery.
[24] V. Perry,et al. Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.
[25] A. James,et al. Effect of temporal sparseness and dichoptic presentation on multifocal visual evoked potentials , 2005, Visual Neuroscience.
[26] Frederik Barkhof,et al. Assessing treatment effects on axonal loss—evidence from MRI monitored clinical trials , 2004, Journal of Neurology.
[27] R. Lynch. Applied Factor Analysis in the Natural Sciences , 1997 .